Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1987 Oct;62(2):279–284.

Pathways of human B-lymphocyte activation blocked by B-cell specific monoclonal antibodies.

J T Golay 1, D H Crawford 1
PMCID: PMC1453973  PMID: 2824347

Abstract

The data presented in this report demonstrate that antibodies directed against B-cell specific surface antigens can block different modes of B-cell activation. The anti-CD 19 antibody HD37 strongly blocks the stimulation of thymidine incorporation induced by anti-mu and MLR supernatant and also partially inhibits the growth of long-term EBV-transformed cell lines. The anti-CD20 antibody B1, on the other hand, has little effect on anti-mu activation but prevents the stimulation of thymidine incorporation and transformation by EBV. We conclude that different mechanisms operate during B-cell activation by anti-mu and EBV involving different B-cell surface molecules.

Full text

PDF
279

Images in this article

282Figure 2
on p.282

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clark E. A., Shu G., Ledbetter J. A. Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc Natl Acad Sci U S A. 1985 Mar;82(6):1766–1770. doi: 10.1073/pnas.82.6.1766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dongworth D. W., Klaus G. G. Effects of cyclosporin A on the immune system of the mouse. I. Evidence for a direct selective effect of cyclosporin A on B cells responding to anti-immunoglobulin antibodies. Eur J Immunol. 1982 Dec;12(12):1018–1022. doi: 10.1002/eji.1830121207. [DOI] [PubMed] [Google Scholar]
  3. Fauci A. S., Pratt K. R., Whalen G. Activation of human B lymphocytes. II. Cellular interactions in the PFC response of human tonsillar and peripheral blood B lymphocytes to polyclonal activation by pokeweed mitogen. J Immunol. 1976 Dec;117(6):2100–2104. [PubMed] [Google Scholar]
  4. Golay J. T., Clark E. A., Beverley P. C. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol. 1985 Dec;135(6):3795–3801. [PubMed] [Google Scholar]
  5. Kehrl J. H., Muraguchi A., Fauci A. S. Differential expression of cell activation markers after stimulation of resting human B lymphocytes. J Immunol. 1984 Jun;132(6):2857–2861. [PubMed] [Google Scholar]
  6. Martínez-Maza O., Britton S. Frequencies of the separate human B cell subsets activatable to Ig secretion by Epstein-Barr virus and pokeweed mitogen. J Exp Med. 1983 Jun 1;157(6):1808–1814. doi: 10.1084/jem.157.6.1808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Muraguchi A., Butler J. L., Kehrl J. H., Falkoff R. J., Fauci A. S. Selective suppression of an early step in human B cell activation by cyclosporin A. J Exp Med. 1983 Sep 1;158(3):690–702. doi: 10.1084/jem.158.3.690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Muraguchi A., Fauci A. S. Proliferative responses of normal human B lymphocytes. Development of an assay system for human B cell growth factor (BCGF). J Immunol. 1982 Sep;129(3):1104–1108. [PubMed] [Google Scholar]
  9. Reedman B. M., Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer. 1973 May;11(3):499–520. doi: 10.1002/ijc.2910110302. [DOI] [PubMed] [Google Scholar]
  10. Tosato G., Blaese R. M., Yarchoan R. Relationship between immunoglobulin production and immortalization by Epstein Barr virus. J Immunol. 1985 Aug;135(2):959–964. [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES